Short answer
Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $280.8M net proceeds from 39,591,000 shares, 3,800,000 pre-funded warrants, and 6,508,650 option shares.
Aura Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $280.8M net proceeds from 39,591,000 shares, 3,800,000 pre-funded warrants, and 6,508,650 option shares
- $241.8M earmarked for clinical programs, bel-sar registration activities, and general corporate purposes
- $39.0M allocated to repurchase 6,922,870 shares from Matrix at $5.64 per share
- Financing expected to fund operating expenses and capital requirements into the second half of 2028
- Immediate equity issuance creates substantial dilution, partially offset by the planned stock repurchase
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aura Biosciences, Inc. 8-K filings
Get the next AURA 8-K as it lands
Follow AURA for push alerts, or ask the research agent what this filing means.